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Abstract: A series of novel oxazolo[5,4-d]pyrimidines was designed via a scaffold 
hopping strategy and synthesized through a newly developed approach. All these 
compounds were evaluated for their biological activity toward CB1/CB2 cannabinoid 
receptors, their metabolic stability in mice liver microsomes and their cytotoxicity 
against several cell lines. Eight compounds have been identified as CB2 ligands with 
Ki values less than 1 μM. It is noteworthy that 
2-(2-chlorophenyl)-5-methyl-7-(4-methylpiperazin-1-yl) oxazolo[5,4-d]pyrimidine 47 
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and 2-(2-chlorophenyl)-7-(4-ethylpiperazin-1-yl)- 5-methyloxazolo[5,4-d]pyrimidine 
48 showed CB2 binding affinity in the nanomolar range and significant selectivity 
over CB1 receptors. Interestingly, functionality studies imply that they behave as 
competitive neutral antagonists. Moreover, all tested compounds are devoid of 
cytotoxicity toward several cell lines, including Chinese hamster ovary cells (CHO) 
and human colorectal adenocarcinoma cells HT29.  
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1. Introduction 
The endocannabinoid system (ECS), present in mammals and comprising two 
primary G protein-coupled receptors, is linked with endogenous lipid mediators and 
relevant enzymes responsible for the synthesis and degradation of lipid mediators [2]. 
Due to its functions in the regulation of pain, inflammation, motor behavior, emotion, 
appetite and addiction, the ECS has been regarded as an ideal target with broad 
therapeutic potential [2-4]. The two G protein-coupled cannabinoid CB1 and CB2 
receptors, are predominantly expressed in the central nervous system (e.g. brain) and 
immune cells (e.g. macrophages), respectively [3, 5-7]. CB1 receptor antagonists have 
shown potential in the treatment of addiction and obesity. It has been demonstrated 
that the administration of a CB1 antagonist (e.g., rimonabant) brings about a reduction 
of drug-seeking behaviors and weight loss [8-11]. By contrast, CB2 receptor agonists 
lead to down regulation of inflammation and pain by restoring the equilibrium 
between pro- and anti-inflammatory cytokines [3, 5, 7, 12]. Moreover, several studies 
have shown that CB2 inverse agonists can regulate bone proliferation and relieve 
inflammation through modulating the migration of immune cells [13-15]. However, 
research on CB2 neutral antagonists is rare, and their therapeutic potential remains 
unknown. In some cases, CB2 neutral antagonists can be considered as ideal tools for 
investigating the biological function of receptors due to their ability to combine with 
receptors without altering corresponding biomolecular levels [16, 17]. In addition, 
targeting CB1 receptors rather than CB2 receptors has been demonstrated to induce 
tetrahydrocannabinol-like side effects (e.g., hypomotility, hypothermia, catalepsy) 
[18]. Thus, the development of selective CB2 ligands has been considered as an 
interesting therapeutic strategy. 
Over the course of the last few decades, the development of CB2 ligands has 
significantly progressed. Numerous selective CB2 ligands have shown therapeutic 
potential in a wide range of in vivo models, including pain, inflammation, cancer, 
immune disorders, neurodegenerative diseases and bone disorders [14, 19-26]. 
Specifically, more than ten CB2 selective agonists have been reported to be under 
evaluation in clinical trials for the treatment of inflammation and pain [12]. For 
instance, compound 1 (GRC10693, Figure 1), developed by Glenmark 
Pharmaceuticals, successfully completed Phase I trials in 2009 [27]. It was intended to 
be used for pain remission, including neuropathic pain and inflammatory pain. 
Moreover, Eli Lilly and Co. disclosed a series of purines as selective CB2 agonists 
[28-31]. Of note, compound 2 (LY2828360, Figure 1), derived from the lead 
compound 3 (Figure 1), has been recognized as a potent and efficacious analgesic 
agent in a rat model of osteoarthritis related chronic pain at a 1 mg/kg oral dose [30]. 
Accordingly, clinical trials for the treatment of osteoarthritic knee pain were 
performed [32]. Additionally, it was reported that compound 4 (AM630, Figure 2), 
one of the most potent CB2 inverse agonist identified to date, can attenuate 
osteoporosis [25, 33, 34]. Two other notable CB2 inverse agonists, 5 (Sch225336, 
Figure 2) and 6 (Sch414319, Figure 2), have been shown to reduce inflammation 
through modulating the recruitment of immune cells [13, 15]. 
 
Figure 1. Structures of representative CB2 agonists evaluated in clinical trials. 
 
Figure 2. Representative CB2 inverse agonists. 
Scaffold hopping is a useful and powerful strategy for drug discovery. It has been 
widely used for the design of potential bioactive molecules [35-37]. In general, 
scaffold hopping incorporate heterocycle replacement, ring opening and closure, 
pseudopeptides and peptidomimetics, and topology/shape-based scaffold hopping [36]. 
Herein, we applied the heterocycle replacement-based scaffold hopping strategy 
toward compound 3, a CB2 agonist developed by Eli Lilly and Co [30]. 
Oxazolo[5,4-d]pyrimidine is a versatile scaffold used for the design of bioactive 
ligands against enzymes or receptors [38-40]. Hence, we replaced the purine core by 
this scaffold, with the intention of observing its influence on bioactivity toward CB2 
receptors (Figure 3). Afterwards, we carried out pharmacomodulations around the 
oxazolopyrimidine core (Figure 4). The newly synthesized compounds were tested for 
their CB2 vs CB1 affinity in a binding assay, their efficacy toward CB2, and their 
metabolic stability in mice liver microsomes. 
 
Figure 3. Heterocycle replacement-based scaffold hopping toward compound 3. 
 Figure 4. Structural modifications of substituents on the oxazolo[5,4-d]pyrimidine core. 
2. Results and discussion 
2.1. Chemistry 
Compounds 11-14 were prepared by a cyclisation reaction between benzoyl 
chloride or ortho-halogenated benzoyl chloride derivatives and aminomalononitrile 
p-toluenesulfonate (75-90% yields). Starting from these compounds, target 
compounds were obtained through three different synthetic pathways (Scheme 1): (I) 
5-amino-2-(2-chlorophenyl)oxazole-4-carbonitrile (13) reacted with formamidine 
acetate to generate 2-(2-chlorophenyl)oxazolo[5,4-d]pyrimidin-7-amine 15 (86% 
yield), which was further involved in a nucleophilic substitution using 15 wt. % 
potassium bis(trimethylsilyl)amide (KHMDS) solution in toluene and brominated 
derivatives to either give target compounds 17-20 (37-52% yields) directly, or to 
afford a tert-butyloxycarbonyl (Boc)-protected precursor 16 (43% yield). 
Deprotection of the Boc group of 16 using trifluoroacetic acid (TFA) followed by 
neutralisation yielded compound 21 (99% yield). (II) Alternatively, compounds 11-14 
were cyclized using formic acid to give 2-phenyloxazolo[5,4-d]pyrimidin-7-ones 
22-25 (33-46% yields), respectively. Afterwards, POCl3-dependent chlorination 
converted these 2-phenyloxazolo[5,4-d]pyrimidin-7-ones into compounds 26-29 
(72-85% yields). The chloride group of 26-29 was substituted by a piperazine or 
morpholine derivative to either give target compounds 32-42 (98-99% yields) directly, 
or to afford Boc-protected compound 30 (98% yield). Compound 43 (98% yield) was 
obtained after deprotection of the piperazine group of compound 30 using TFA 
followed by a nucleophilic substitution on bromopropane. (III) Additionally, 
compound 13 was acetylated to afford 44 (78% yield) in the presence of acetyl 
chloride and N,N-diisopropylethylamine (DIPEA). A solution of 44 in 30% NaOH and 
35% H2O2 was refluxed to give 45 (69% yield), which was further chlorinated by 
POCl3 (77% yield) and substituted with piperazine derivatives to produce compounds 
47-48 (98-99% yields). 
 
Scheme 1. Synthetic routes to prepare compounds 17-21, 32-43, and 47-48. (a) 
aminomalononitrile p-toluenesulfonate, NMP, microwave, 80 °C, 25 min, 75-90%. (b) 
formamidine acetate, NMP, 100 °C, 3 h, 86%. (c) KHMDS, 15 wt. % in toluene, brominated 
derivative, DMF, room temperature (rt), 3 h, 37-52%. (d) TFA, CH2Cl2, rt, 3 h, 99%. (e) formic 
acid, reflux, overnight, 31-37%. (f) POCl3, DIPEA, toluene, rt, 2 h, 72-85%. (g) piperazine 
derivative or morpholine, Cs2CO3, DMF, 100 °C, 30 min, 98-99%. (h) bromopropane, Cs2CO3, 
DMF, 100 °C, 30 min, 99%. (i) acetyl chloride, DIPEA, NMP, 45 °C, 6 h, 78%. (j) 30% NaOH 
and 35% H2O2 in water, reflux, 2 h, 61%. 
2.2. In vitro binding assays and cytotoxicity 
The affinities of each synthesized compound for CB receptors were determined 
by a competitive radioligand displacement assay using the dual CB1/CB2 ligand 
[3H]-CP55,940 [22, 41]. All compounds were first screened at the concentration of 1 
μM. The binding affinities (Ki) were calculated using the Cheng-Prusoff equation 
based on the experimental IC50 values for compounds exhibiting a competitive 
binding superior to 50% for CB2. Kd values of CP-55,940 towards CB1 and CB2 are 
0.62 and 0.85 nM, respectively. 
As illustrated in Table 1, compounds 47 and 48 bearing a chlorine at the ortho 
position of the phenyl ring, a C5-substituted methyl group, and a C7-substituted 
piperazine moiety, possess the best affinities toward CB2 receptors, in the double-digit 
nanomolar range, with good selectivity over CB1 receptors (SI > 12). The removal of 
the C5-substituted methyl group of 47 and 48 (Ki = 27.5 nM and 23 nM, respectively) 
leads to a sharp decrease in CB2 binding affinities (i.e. compounds 40 and 41, Ki = 
350 and 329 nM, respectively). These results imply that the methyl group at the C5 
position plays a crucial role in binding affinity for CB2, probably due to hydrophobic 
interactions with the receptor. In general, C7-substituted piperazine derivatives (40-42, 
Ki values range from 350 nM to 678 nM) are preferred over morpholine (39, Ki > 
1000 nM) or secondary amine substituents (17-21, Ki > 1000 nM). Of note, 
compounds bearing an N-ethylpiperazine at the C7 position (37, 41, and 48, Ki = 95.5 
nM, 329 nM, and 23 nM, respectively) possess slightly superior CB2 binding affinities 
than the corresponding compounds bearing a N-methylpiperazine (36, 40, and 47, Ki = 
155 nM, 350 nM, and 27.5 nM, respectively) and are approximately 2-3 times more 
potent CB2 ligands than compounds bearing a N-acetylpiperazine substituent (38 and 
42, Ki = 254 nM and 678 nM, respectively). Specifically, extending the carbon chain 
on the nitrogen at the C7 position of 41 (Ki = 329 nM) from 2C to 3C (43, Ki > 1000 
nM) leads to almost complete loss of CB2 binding affinity. Moreover, large ortho 
substituents (such as CF3, 36-38, Ki values range from 95.5 nM to 254 nM, and Cl, 
40-42, Ki values range from 329 nM to 678 nM) on the phenyl ring contribute to 
better CB2 binding affinities in comparison with small groups (such as F, 34-35, Ki > 
1000 nM, and H, 32-33, Ki > 1000 nM). This observation might be attributed to the 
fact that larger groups make stronger hydrophobic interactions with the CB2 receptor. 
Table 1. Affinities (Ki values) of compounds 17-21, 32-43, 47-48, and reference compounds 3, 4, 
WIN 55,212-2 toward hCB2 and hCB1 cannabinoid receptors, selectivity ratios hCB2 versus hCB1, 
and cytotoxicity on CHO-WT, CHO-CB2, and HT29 Cells. 
     
Compounds R1 R2 
Binding assays (nM)a CB1/CB2 
ratio 
Cytotoxicity assays % inhibition at 10 μM 
Ki hCB2 Ki hCB1 CHO-WT CHO-CB2 HT29 
17 Cl  > 1000 > 1000
 N.D.b 0 18 0 
18 Cl  > 1000 > 1000 N.D.
b 0 0 0 
19 Cl  > 1000 > 1000 N.D.
b 6 13 10 
20 Cl 
 
> 1000 > 1000 N.D.b 0 10 0 
21 Cl 
 
> 1000 > 1000 N.D.b 0 9 41 
 R1 R3      
32 H 
 
> 1000 > 1000 N.D.b 0 0 0 
33 H 
 
> 1000 > 1000 N.D.b 0 0 0 
34 F 
 
> 1000 > 1000 N.D.b 8 7 0 
35 F 
 
> 1000 > 1000 N.D.b 10 8 24 
36 CF3 
 
155 ± 8 > 1000 > 6.4 3 0 0 
37 CF3 
 
95.5 ± 11.5 > 1000 > 10.4 10 5 1 
38 CF3 
 
254 ± 26 > 1000 > 3.9 12 1 12 
39 Cl 
 
> 1000 > 1000 N.D.b 0 10 5 
40 Cl 
 
350 ± 33 > 1000 > 2.8 0 0 8 
41 Cl 
 
329 ± 61 > 1000 > 3.0 1 9 4 
42 Cl 
 
678 ± 84 > 1000 > 1.4 23 11 0 
43 Cl 
 
> 1000 > 1000 N.D.b 0 2 0 
 R1 R4      
47 Cl 
 
27.5 ± 0.5 > 1000 > 36.3 0 4 24 
48 Cl 
 
23 ± 4 293 12.7 0 16 16 
3 (agonist)   51 ± 9 > 1000 > 19.6 30 0 0 
4 (inverse agonist)   91 ± 11 > 1000 > 11.0 0 0 0 
WIN55212-2 
(agonist) 
  3.01 ± 0.99      
a Data represent the mean ± SEM of at least three experiments performed in duplicate or triplicate. 
b
 N.D. means not determined. 
 
In summary, the structure-activity relationship (SAR) studies indicate that 
piperazine moieties at the C7 position favor CB2 binding affinities of the molecules. 
Notably, lipophilic piperazine moieties (i.e., methylpiperazine and ethylpiperazine) 
are preferred for CB2 affinity rather than a hydrophilic piperazine moiety (i.e., 
acetylpiperazine). However, there seems to be steric limitations due to a sudden 
decrease in CB2 binding affinity caused by extending the N-substituted alkyl chain 
from 2C to 3C. Moreover, large ortho substituents on the phenyl ring are beneficial 
for CB2 binding affinities. The introduction of a methyl group at the C5 position 
seems to significantly improve the CB2 binding affinities of the molecules (Figure 5). 
It is noteworthy that the two most potent compounds 47 and 48 (Ki = 27.5 nM and 23 
nM, respectively) manifest CB2 binding affinities twice as potent as the reference 
compound 3 (Ki = 51 nM). This result implies that oxazolo[5,4-d]pyrimidine-based 
compounds can act as effective bioisosteres of purines in terms of CB2 binding. 
Additionally, compounds 47 (SI > 36) and 48 (SI = 12.7) are selective CB2 ligands 
over CB1 receptors. 
 
Figure 5. Structure-affinity relationships of oxazolo[5,4-d]pyrimidine-based CB2 ligands. 
The cytotoxicity of these compounds was determined at 10 μM using a cell 
proliferation assay on Chinese hamster ovary cells wild type (CHO-WT), Chinese 
hamster ovary cells expressing CB2 receptors (CHO-CB2), and human colorectal 
adenocarcinoma cells HT29. This test is based on a colorimetric method, which 
measures the activity of cellular enzymes that reduce the tetrazolium dye (MTS, 
yellow) to its insoluble formazan, giving a purple color. This assay measures cellular 
metabolic activity via NADPH-dependent cellular oxidoreductase enzymes and 
reflects, under defined conditions, the number of viable cells [5, 42]. No significant 
cytotoxicity over 72h was observed for these new compounds. 
2.3. Cyclic adenosine monophosphate (cAMP) assays 
Eight compounds displaying potent CB2 affinity were further studied for their 
functionality by cAMP assays in CHO-CB2 cells. Cells were treated with forskolin (3 
μM) in order to activate adenylyl cyclase and thereby producing cAMP [43-45]. CB2 
ligands can be classified as agonists, neutral antagonists, or inverse agonists regarding 
to their functional effects on cAMP formation. Agonists inhibit forskolin-induced 
cAMP production, whereas inverse agonists promote cAMP production. On the 
contrary, neutral antagonists do not significantly alter cAMP levels [46, 47]. As shown 
in Table 2, the maximum efficacy (Emax) of a compound represents the maximum 
response at 1 μM and is expressed as the percentage of forskolin-induced cAMP 
production [5]. Despite their potent binding affinities toward CB2 receptors, these 
compounds did not significantly affect CB2-mediated regulation of cAMP 
accumulation (Emax values range from 88% to 131%), compared with forskolin 
(100%). Data in Figure 6 further demonstrated that compounds 47 and 48 showed 
competitive antagonist properties. These two compounds remarkably antagonized 
CB2 agonist (0.1 μM WIN 55,212-2)-induced inhibition of cAMP formation at 1 μM 
and almost completely restored forskolin-induced cAMP levels at 10 μM. IC50 values 
of these two compounds are 0.93 μM (47) and 0.12 μM (48), respectively. 
Interestingly, although replacement of the purine core by oxazolo[5,4-d]pyrimidine 
does not alter the binding affinity of the molecule toward CB2, it appears to alter the 
biological response from a CB2 agonist to competitive neutral antagonist. 
Table 2. Maximum efficacy (Emax) of compounds 36-38, 40-42, 47-48, and reference compounds 
3, 4, WIN 55,212-2 at 1 μM. 
Compounds CB2 cAMP assays Emax (%)a 
36 129 ± 3 
37 117 ± 15 
38 107 ± 16 
40 131 ± 13 
41 120 ± 8 
42 117 ± 7 
47 94 ± 2 
48 88 ± 7 
forskolin 100 
3 (agonist) 71 ± 3 
4 (inverse agonist) 863 ± 28 
WIN55212-2 (agonist) 64 ± 12 
a Data represent the mean ± SEM of at least three independent experiments performed in duplicate or 
triplicate. Emax values are expressed as the percentage of forskolin-induced cAMP production. Forskolin 
(3 μM) effect was set to 100%. 
 
Figure 6. Inhibition of forskolin-stimulated cAMP formation by WIN 55,212-2 (0.1 μM) and 
antagonism by 47 and 48 (0.1-10 μM) in CB2-CHO cells. Forskolin (3 μM) effect was set to 100%. 
Data represent the mean ± SEM of at least three experiments performed in duplicate. 
2.4. Metabolic stability in mice liver microsomes 
These eight potent CB2 ligands have also been examined for their in vitro 
metabolic stability in the presence of mice liver microsomes (Figure 7, Table 3). It 
was found that almost all of compounds 36, 37, 40 and 41 were rapidly eliminated 
under 5 min (t1/2 ≈ 1 min). Compounds 47 and 48 showed lower intrinsic clearance 
(t1/2 = 4.1 and 8.1 min respectively) than compounds 40 and 41 (t1/2 = 1.3 and 1.2 min 
respectively). This observation implies that a C5-substituted methyl group confers 
higher metabolic stability to the molecules[48], although the clearance values are still 
rather high. In addition, the replacement of an N-alkyl group by an N-acetyl group on 
the piperazine moiety (38 and 42, t1/2 = 12.5 and 12.2 min respectively) has been 
deemed to endow the molecules with significantly improved metabolic stability. 
Although these eight newly synthesized compounds are less metabolically stable than 
compounds 3 in mice liver microsomes, the study of their structure-stability 
relationships may be helpful to further improve the metabolic stability of 
oxazolo[5,4-d]pyrimidine derivatives. 
 Figure 7. Metabolic stability of compounds 36-38, 40-42, 47, 48, 3, and propranolol. 
Table 3. Clint and t1/2 of compounds 36-38, 40-42, 47, 48, and 3 in the presence of mice liver 
microsomes. 
Compounds Clint (μL/min/mg)a t1/2 (min) 
36 1257 0.9 
37 1236 1.0 
38 174 12.5 
40 1178 1.3 
41 1101 1.2 
42 194 12.2 
47 502 4.1 
48 263 8.1 
3 54 44 
a Clint = dose/AUC, expressed as µL/min/mg proteins. 
3. Conclusion and perspective 
A novel series of oxazolo[5,4-d]pyrimidines has been synthesized. Some of them 
display potent affinity toward CB2 at nanomolar concentrations and significant 
selectivity over CB1. Especially, compounds 47 and 48 have been identified as 
competitive neutral antagonists. Our studies indicate that 
oxazolo[5,4-d]pyrimidine-based compounds can act as effective bioisosteres of 
purines in CB2 binding. Interestingly, such a replacement changes the biological 
response from a CB2 agonist to a competitive neutral antagonist. 
There are many reports on CB2 agonists and inverse agonists but few in the case 
of neutral antagonists. During the last few years, several clinical trials of CB2 agonists 
have been launched. The therapeutic potential of CB2 inverse agonists has also 
progressed. To the best of our knowledge, research on neutral antagonists is rare. 
Indeed, the first reported antagonist SR144528 was then identified to behave as an 
inverse agonist [16, 49]. Some purported “antagonists” are actually inverse agonists 
[50-54]. The real first reported CB2 neutral antagonist may be WIN55212-3 (Figure 8), 
an enantiomer of WIN55212-2, but it showed weak affinity toward CB2 (Ki > 1 μM). 
Another reported CB2 neutral antagonist is XIE35-1001 (Figure 8) [55]. However, 
data in a cAMP assay or [35S]-GTPγS assay are missing. Recently, Bertini and 
coworkers described a non-competitive CB2 neutral antagonist (49, Figure 8) [56], 
which significantly reversed CB2 agonist (1 nM HU-210) responses at 10 μM but did 
not alter maximal responses of the agonist (0.1 μM HU-210) even at 20 μM in a 
[35S]-GTPγS assay. On the contrary, our two neutral antagonists 47 and 48 remarkably 
reversed CB2 agonist (0.1 μM WIN 55,212-2)-induced inhibition of cAMP formation 
at 1 μM. This observation makes compounds 47 and 48 useful tools for studying the 
function of CB2 receptors at the cellular level. 
 In this context, we identified that oxazolo[5,4-d]pyrimidine could be a useful 
scaffold for the development of new selective neutral antagonists toward CB2. 
Moreover, although CB2 inverse antagonists have shown therapeutic potential in 
bone-dependent disorders and inflammation through somehow modulating the 
migration of immune cells, relevant mechanisms remain unclear. The discovery of 
new CB2 neutral antagonists with high affinity might be helpful for elucidating how 
CB2 inverse agonists regulate bone proliferation and the migration of immune cells. 
Notably, compounds 47 and 48, which display nanomolar potency and behave as 
competitive neutral antagonists toward CB2, may serve as lead compounds for further 
studies. Furthermore, we will continue the structural optimization of these 
oxazolepyrimidines to improve their metabolic stability so that they can be suitable 
for systemic applications. 
Figure 8. Structures of representative CB2 neutral antagonists. 
4. Experimental section 
4.1. Chemistry 
4.1.1. General procedures 
All reactions involving air or moisture-sensitive compounds were performed 
under argon atmosphere. Solvents and reagents were purchased from commercial 
suppliers and were used without further purification. The thin layer chromatography 
was performed using silica gel plates (Polygram Sil G/UV254, thickness: 0.2 mm, ref. 
805023 Macherey Nagel). The revelation was made under UV (253 and 366 nm). The 
purifications by column chromatography were performed using silica gel 60, 
granulometry 40-63 μm (ref. 9385.5000 Merck). The microwave reactions were 
performed using a CEM DiscoverSP. Melting points were recorded on a Büchi 
melting point apparatus and are uncorrected. They are expressed in degrees Celsius. 
NMR spectra were recorded at 300 (1H) and 75 (13C) MHz on a Bruker AC300P 
Fourier transform spectrometer. Chemical shifts () are reported relative to 
tetramethylsilane (TMS) as the internal standards in the NMR laboratory of Physical 
Chemistry of University Lille 2. Spectra were recorded at ambient temperature. Each 
signal is identified by its chemical shift δ expressed in parts per million (ppm). 
Coupling constant (J) is reported in Hertz (Hz). All target compounds were 
characterized by LC-MS and HRMS. The high performance liquid chromatograph 
(ODS column, mobile phase: H2O/CH3CN/HCOOH using gradient method) is 
coupled to a UV detector and a type of APCI+ (atmospheric pressure chemical 
ionization) mass detector. HRMS analyzes were performed under ESI (electrospray 
ionization) using a TOF analyzer in V mode with a mass resolution of 9000. The 
spectra were recorded at the Centre Universitaire des Mesures Analytique of 
University Lille 2 using Thermo Electron Surveyor MSQ mass spectrometer. The 
purity of all compounds was determined by HPLC using a Chromazing column (4.6 x 
150 mm, 5 μm, 100 Å, mobile phase: CH3CN/H2O/HCOOH = 100/25/1) and a 
WATERS 600 pump chromatograph equipped with a WATERS 2487 dual absorption 
wavelength UV detector (λ = 254 nm and 366 nm). Retention time was obtained with 
flow rates of 1 mL/min. The acquisition time is 20 min. 
4.1.2. Synthesis of 5-amino-2-(2-substituted phenyl)oxazole-4-carbonitriles (11-14) 
A solution of benzoyl chloride or ortho halogenated benzoyl chloride (4.8 mmol, 
1.2 equiv) and aminomalononitrile p-toluenesulfonate (4 mmol, 1 equiv) in 15 mL 
NMP was stirred at room temperature for 10 min, and then heated by microwave 
irradiation at 80 °C for 25 min. At the end of the reaction, after cooling, the solution 
was diluted with 100 mL saturated brine and neutralized (pH ~8) to give a white 
precipitate, which was further recrystallized in CH2Cl2 to afford compounds 11-14. 
These compounds were used for the next reaction. 
4.1.3. Synthesis of 2-(2-chlorophenyl)oxazolo[5,4-d]pyrimidin-7-amine (15) 
A solution of compound 13 (2.5 mmol, 1 equiv) and formamidine acetate (3 
mmol, 1.2 equiv) in 15 mL NMP was stirred and heated at 100 °C for 3 h. At the end 
of the reaction, after cooling, the solution was diluted with 100 mL saturated brine to 
give a white precipitate, which was recrystallized in CH2Cl2 to afford compound 15. 
This compound was used for the next reaction. 
4.1.4. Synthesis of 2-(2-chlorophenyl)-N-alkyloxazolo[5,4-d]pyrimidin-7-amines 
(16-20) 
To a solution of compound 15 (0.25 mmol, 0.1 equiv) and brominated derivative 
(0.2 mmol, 0.8 equiv) in 15 mL DMF, cooled to 0 °C, 15 wt. % KHMDS (0.3 mmol, 
1.2 equiv) solution in toluene was added dropwise. Afterwards, the mixture solution 
was recovered to room temperature and stirred for 3 h. At the end of the reaction, the 
solution was diluted with 100 mL saturated brine, and then extracted with 80 mL ethyl 
acetate. The organic phase was washed twice with 50 mL distilled water and dried 
over MgSO4. The solvent was evaporated under reduced pressure. The residue was 
purified by silica gel column chromatography using CH2Cl2/ethyl acetate (8: 2 v/v) as 
eluent to give compounds 16-20. 
4.1.4.1. N-Butyl-2-(2-chlorophenyl)oxazolo[5,4-d]pyrimidin-7-amine (17) 
The title compound was obtained as a white solid, mp 104-105 °C, purity 
(HPLC): 98.8%. 1H NMR (300 MHz, DMSO-d6) δ 8.46 – 8.19 (m, 2H), 8.09 (d, J = 
7.8 Hz, 1H), 7.72 (dd, J = 7.9, 1.6 Hz, 1H), 7.70 – 7.52 (m, 2H), 3.90 – 3.71 (m, 
0.5H), 3.62 – 3.41 (m, 1.5H), 1.73 – 1.50 (m, 2H), 1.48 – 1.27 (m, 2H), 0.92 (t, J = 
7.3 Hz, 3H). 13C NMR (75 MHz, DMSO-d6) δ 164.1 (C), 156.2 (C), 155.5 (C), 155.2 
(CHA), 154.8 (CHB), 133.3 (CH), 132.4 (C), 132.2 (CH), 131.7 (CH), 128.2 (CH), 
125.8 (C), 116.1 (C), 42.7 (CH2B), 40.3 (CH2A), 32.5 (CH2B), 31.4 (CH2A), 20.1 (CH2), 
14.2 (CH3). HRMS (ESI) calcd. for C15H15ON4Cl ([M+H]
+) 303.10072, found 
303.10004. 
4.1.4.2. 2-(2-Chlorophenyl)-N-(2-methoxyethyl)oxazolo[5,4-d]pyrimidin-7-amine 
(18) 
The title compound was obtained as a white solid, mp 124-125 °C, purity 
(HPLC): 95.1%. 1H NMR (300 MHz, DMSO-d6) δ 8.43 – 8.20 (m, 2H), 8.10 (dd, J = 
7.6, 2.0 Hz, 1H), 7.72 (dd, J = 7.8, 1.6 Hz, 1H), 7.70 – 7.52 (m, 2H), 4.09 – 3.88 (m, 
0.5H), 3.76 – 3.64 (m, 1.5H), 3.63 – 3.51 (m, 2H), 3.28 (s, 3H). 13C NMR (75 MHz, 
DMSO-d6) δ 164.1 (C), 156.3 (C), 155.5 (C), 155.1 (CH), 133.3 (CH), 132.4 (C), 
132.2 (CH), 131.7 (CH), 128.2 (CH), 125.7 (C), 116.3 (C), 71.4 (CH2B), 70.5 (CH2A), 
58.4 (CH3), 42.6 (CH2B), 40.1 (CH2A). HRMS (ESI) calcd. for C14H13O2N4Cl 
([M+H]+) 305.07998, found 305.07927. 
4.1.4.3. 2-(2-Chlorophenyl)-N-pentyloxazolo[5,4-d]pyrimidin-7-amine (19) 
The title compound was obtained as a white solid, mp 122-123 °C, purity 
(HPLC): 98.4%. 1H NMR (300 MHz, DMSO-d6) δ 8.43 – 8.19 (m, 2H), 8.08 (dd, J = 
7.5, 1.9 Hz, 1H), 7.70 (dd, J = 7.9, 1.5 Hz, 1H), 7.68 – 7.50 (m, 2H), 3.86 – 3.68 (m, 
0.5H), 3.58 – 3.41 (m, 1.5H), 1.72 – 1.49 (m, 2H), 1.38 – 1.25 (m, 4H), 0.86 (t, J = 
6.7 Hz, 3H). 13C NMR (75 MHz, DMSO-d6) δ 164.1 (C), 156.2 (C), 155.5 (C), 155.2 
(CHA), 154.8 (CHB), 133.3 (CH), 132.4 (C), 132.2 (CH), 131.7 (CH), 128.2 (CH), 
125.8 (C), 116.1 (C), 43.0 (CH2B), 40.8 (CH2A), 30.0 (CH2B), 29.0 (CH2A × 2), 22.4 
(CH2), 14.4 (CH3). HRMS (ESI) calcd. for C16H17ON4Cl ([M+H]
+) 317.11637, found 
317.11586. 
4.1.4.4. 2-(2-Chlorophenyl)-N-(cyclohexylmethyl)oxazolo[5,4-d]pyrimidin-7-amine 
(20) 
The title compound was obtained as a solid, mp 140-141 °C, purity (HPLC): 
97.6%. 1H NMR (300 MHz, DMSO-d6) δ 8.45 – 8.20 (m, 2H), 8.08 (d, J = 7.7 Hz, 
1H), 7.76 – 7.66 (m, 1H), 7.69 – 7.51 (m, 2H), 3.70 – 3.57 (m, 0.5H), 3.36 (t, J = 6.4 
Hz, 1.5H), 1.83 – 1.55 (m, 6H), 1.28 – 1.11 (m, 3H), 1.06 – 0.86 (m, 2H). 13C NMR 
(75 MHz, DMSO-d6) δ 164.1 (C), 156.2 (C), 155.7 (C), 155.1 (CHA), 154.8 (CHB), 
133.3 (CH), 132.4 (C), 132.3 (CH), 131.7 (CH), 128.2 (CH), 125.8 (C), 116.1 (C), 
48.9 (CH2B), 46.7 (CH2A), 38.6 (CHB), 37.6 (CHA), 30.9 (CH2 × 2), 26.6 (CH2), 25.8 
(CH2 × 2). HRMS (ESI) calcd. for C18H20ON4Cl ([M+H]
+) 343.13202, found 
343.13139. 
4.1.5. Synthesis of 2-(2-chlorophenyl)-N-(piperidin-4-ylmethyl)oxazolo[5,4-d] 
pyrimidin-7-amine (21) 
To a solution of compound 16 (0.2 mmol, 1 equiv) in 50 mL CH2Cl2 was added 
TFA (2 mmol, 10 equiv). The mixture was stirred at room temperature for 3 h. At the 
end of the reaction, the solvent was removed under reduced pressure and the residue 
was dissolved in water and the solution was neutralised to pH 9 using 30% NaOH, 
then the solution was extracted with ethyl acetate. The organic layer was washed with 
brine and distilled water successively, dried over MgSO4 and evaporated under 
reduced pressure to give compound 21. The title compound was obtained as a white 
solid, mp > 270 °C, purity (HPLC): 96.8%. 1H NMR (300 MHz, DMSO-d6) δ 8.53 – 
8.19 (m, 2H), 8.09 (d, J = 7.6 Hz, 1H), 7.71 (dd, J = 7.8, 1.6 Hz, 1H), 7.70 – 7.51 (m, 
2H), 3.71 – 3.61 (m, 0.5H), 3.44 – 3.33 (m, 1.5H), 3.00 – 2.84 (m, 2H), 2.46 – 2.31 
(m, 2H), 1.88 – 1.52 (m, 3H), 1.20 – 0.92 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 
164.1 (C), 156.2 (C), 155.7 (C), 155.1 (CHA), 154.8 (CHB), 133.3 (CH), 132.4 (C), 
132.2 (CH), 131.7 (CH), 128.2 (CH), 125.8 (C), 116.1 (C), 48.9 (CH2B), 46.7 (CH2A), 
46.3 (CH2 × 2), 37.7 (CHB), 36.6 (CHA), 31.5 (CH2), 31.2 (CH2). HRMS (ESI) calcd. 
for C17H19ON5Cl ([M+H]
+) 344.12726, found 344.12650. 
4.1.6. Synthesis of 2-(2-substituted phenyl)oxazolo[5,4-d]pyrimidin-7-ols (22-25) 
To a solution of compound 11, 12, 13, or 14 (1 mmol) in 20 mL formic acid was 
refluxed overnight. At the end of the reaction, after cooling, formic acid was removed 
under reduced pressure. The residue was purified by silica gel column 
chromatography using CH2Cl2/ethyl acetate (6: 4 v/v) as eluent to give compound 22, 
23, 24, or 25, respectively. 
4.1.7. Synthesis of 7-chloro-2-(2-substituted phenyl)oxazolo[5,4-d]pyrimidines 
(26-29) 
To a solution of compound 22, 23, 24, or 25 (0.5 mmol, 1 equiv) in 30 mL 
toluene were added DIPEA (0.75 mmol, 1.5 equiv) and POCl3 (1.5 mmol, 3 equiv) 
successively at 0 °C. The mixture was stirred for 2 h. At the end of the reaction, the 
solvent was removed under reduced pressure. The residue was purified by silica gel 
column chromatography using CH2Cl2/ethyl acetate (95: 5 v/v) as eluent to give 
compound 26, 27, 28, or 29, respectively. 
4.1.8. Synthesis of 2-(2-substituted phenyl)-7-(4-substituted piperazinyl or 
morpholine)oxazolo[5,4-d]pyrimidines (30, 32-42) 
To a solution of compound 26, 27, 28, or 29 (0.15 mmol, 1 equiv) in 15 mL 
DMF were added Cs2CO3 (0.3 mmol, 2 equiv) and piperazine derivative/morpholine 
(0.18 mmol, 1.2 equiv). The mixture was stirred and heated at 100 °C for 30 min. At 
the end of the reaction, the solution was diluted with 50 mL saturated brine, and then 
extracted twice with 30 mL ethyl acetate. The organic phase was washed twice with 
50 mL distilled water and dried over MgSO4. The solvent was evaporated under 
reduced pressure to give pure target compound directly or crude compound, which 
was purified by silica gel column chromatography using ethyl acetate/methanol (98: 2 
v/v) as eluent. 
4.1.8.1. 7-(4-Methylpiperazin-1-yl)-2-phenyloxazolo[5,4-d]pyrimidine (32) 
The title compound was obtained as a yellow solid, mp 136-137 °C, purity 
(HPLC): 99.3%. 1H NMR (300 MHz, CDCl3) δ 8.36 (s, 1H), 8.24 – 8.13 (m, 2H), 
7.56 – 7.46 (m, 3H), 4.55 – 4.06 (m, 4H), 2.64 – 2.52 (m, 4H), 2.38 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ 165.5 (C), 157.5 (C), 154.1 (C), 153.7 (CH), 131.6 (CH), 128.9 
(CH × 2), 127.3 (CH × 2), 126.5 (C), 116.9 (C), 55.0 (CH2 × 2), 46.2 (CH3), 45.1 
(CH2 × 2). HRMS (ESI) calcd. for C16H18ON5 ([M+H]
+) 296.15059, found 296.14967. 
4.1.8.2. 7-(4-Ethylpiperazin-1-yl)-2-phenyloxazolo[5,4-d]pyrimidine (33) 
The title compound was obtained as a yellow solid, mp 120-121 °C, purity 
(HPLC): 99.3%. 1H NMR (300 MHz, CDCl3) δ 8.36 (s, 1H), 8.25 – 8.12 (m, 2H), 
7.56 – 7.47 (m, 3H), 4.57 – 4.00 (m, 4H), 2.70 – 2.57 (m, 4H), 2.50 (q, J = 7.1 Hz, 
2H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 165.5 (C), 157.5 (C), 
154.1 (C), 153.7 (CH), 131.5 (CH), 128.9 (CH × 2), 127.3 (CH × 2), 126.5 (C), 116.8 
(C), 52.8 (CH2 × 2), 52.4 (CH2), 44.9 (CH2 × 2), 11.9 (CH3). HRMS (ESI) calcd. for 
C17H20ON5 ([M+H]
+) 310.16624, found 310.16501. 
4.1.8.3. 2-(2-Fluorophenyl)-7-(4-methylpiperazin-1-yl)oxazolo[5,4-d]pyrimidine (34) 
The title compound was obtained as a yellow solid, mp 142-143 °C, purity 
(HPLC): 98.1%. 1H NMR (300 MHz, CDCl3) δ 8.38 (s, 1H), 8.19 – 8.11 (m, 1H), 
7.56 – 7.46 (m, 1H), 7.33 – 7.27 (m, 1H), 7.25 – 7.19 (m, 1H), 4.54 – 4.09 (m, 4H), 
2.57 (t, J = 5.0 Hz, 4H), 2.37 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 165.3 (C), 160.67 
(C, d, J = 259.8 Hz), 154.2 (C), 154.0 (CH), 153.8 (C, d, J = 5.7 Hz), 133.1 (CH, d, J 
= 8.5 Hz), 130.1 (CH), 124.5 (CH, d, J = 3.8 Hz), 117.1 (CH, d, J = 21.0 Hz), 116.6 
(C), 115.0 (C, d, J = 10.6 Hz), 55.0 (CH2 × 2), 46.2 (CH3), 45.1 (CH2 × 2). HRMS 
(ESI) calcd. for C16H17ON5F ([M+H]
+) 314.14116, found 314.14037. 
4.1.8.4. 7-(4-Ethylpiperazin-1-yl)-2-(2-fluorophenyl)oxazolo[5,4-d]pyrimidine (35) 
The title compound was obtained as a yellow solid, mp 127-128 °C, purity 
(HPLC): 99.4%. 1H NMR (300 MHz, CDCl3) δ 8.38 (s, 1H), 8.19 – 8.11 (m, 1H), 
7.56 – 7.46 (m, 1H), 7.33 – 7.27 (m, 1H), 7.25 – 7.19 (m, 1H), 4.54 – 4.07 (m, 4H), 
2.61 (t, J = 5.1 Hz, 4H), 2.50 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 165.3 (C), 160.7 (C, d, J = 259.9 Hz), 154.1 (C), 154.0 (CH), 
153.8 (C, d, J = 5.6 Hz), 133.1 (CH, d, J = 8.5 Hz), 130.1 (CH), 124.5 (CH, d, J = 3.9 
Hz), 117.1 (CH, d, J = 21.0 Hz), 116.6 (C), 115.0 (C, d, J = 10.4 Hz), 52.8 (CH2 × 2), 
52.4 (CH2), 45.1 (CH2 × 2), 11.9 (CH3). HRMS (ESI) calcd. for C17H19ON5F ([M+H]
+) 
328.15681, found 328.15533. 
4.1.8.5. 
7-(4-Methylpiperazin-1-yl)-2-(2-(trifluoromethyl)phenyl)oxazolo[5,4-d]pyrimidine 
(36) 
The title compound was obtained as a yellow solid, mp 137-138 °C, purity 
(HPLC): 99.3%. 1H NMR (300 MHz, CDCl3) δ 8.39 (s, 1H), 8.19 – 8.09 (m, 1H), 
7.93 – 7.83 (m, 1H), 7.77 – 7.59 (m, 2H), 4.57 – 3.99 (m, 4H), 2.58 (t, J = 5.0 Hz, 4H), 
2.37 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 165.6 (C), 154.7 (C), 154.3 (CH, C), 
132.0 (CH), 131.6 (CH), 131.1 (CH), 129.0 (C, q, J = 32.2 Hz), 127.4 (CH, q, J = 5.8 
Hz), 125.3 (C), 123.3 (CF3, q, J = 273.7 Hz), 116.6 (C), 54.9 (CH2 × 2), 46.1 (CH3), 
45.1 (CH2 × 2). HRMS (ESI) calcd. for C17H17ON5F3 ([M+H]
+) 364.13797, found 
364.13656. 
4.1.8.6. 
7-(4-Ethylpiperazin-1-yl)-2-(2-(trifluoromethyl)phenyl)oxazolo[5,4-d]pyrimidine (37) 
The title compound was obtained as a yellow solid, mp 104-105 °C, purity 
(HPLC): 98.1%. 1H NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.18 (d, J = 7.3 Hz, 
1H), 8.02 (d, J = 7.3 Hz, 1H), 7.96 – 7.80 (m, 2H), 4.51 – 3.86 (m, 4H), 2.59 – 2.50 
(m, 4H), 2.38 (q, J = 7.1 Hz, 2H), 1.03 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 165.6 (C), 154.7 (C), 154.3 (CH, C), 132.0 (CH), 131.6 (CH), 131.1 (CH), 129.0 (C, 
q, J = 32.2 Hz), 127.4 (CH, q, J = 5.8 Hz), 125.3 (C), 123.3 (CF3, q, J = 271.9 Hz), 
116.6 (C), 52.7 (CH2 × 2), 52.4 (CH2), 45.2 (CH2 × 2), 11.9 (CH3). HRMS (ESI) 
calcd. for C18H19ON5F3 ([M+H]
+) 378.15362, found 378.15199. 
4.1.8.7. 
1-(4-(2-(2-(Trifluoromethyl)phenyl)oxazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)etha
none (38) 
The title compound was obtained as a yellow solid, mp 145-146 °C, purity 
(HPLC): 96.3%. 1H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.19 (d, J = 6.7 Hz, 
1H), 8.07 – 7.98 (m, 1H), 7.96 – 7.83 (m, 2H), 4.45 – 3.89 (m, 4H), 3.71 – 3.55 (m, 
4H), 2.07 (s, 3H). 13C NMR (75 MHz, DMSO-d6) δ 169.0 (C=O), 165.7 (C), 155.1 
(C), 154.6 (CH), 154.2 (C), 133.6 (CH), 132.7 (CH), 132.6 (CH), 127.7 (C, q, J = 
31.9 Hz), 127.9 (CH, q, J = 5.5 Hz), 124.7 (C), 123.9 (CF3, q, J = 273.3 Hz), 116.2 
(C), 45.7 (CH2), 44.9 (CH2 × 2), 41.0 (CH2), 21.7 (CH3). HRMS (ESI) calcd. for 
C18H17O2N5F3 ([M+H]
+) 392.13289, found 392.13206. 
4.1.8.8. 2-(2-Chlorophenyl)-7-morpholinooxazolo[5,4-d]pyrimidine (39) 
The title compound was obtained as a yellow solid, mp 155-156 °C, purity 
(HPLC): 98.2%. 1H NMR (300 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.12 (dd, J = 7.6, 1.9 
Hz, 1H), 7.71 (dd, J = 7.9, 1.4 Hz, 1H), 7.67 – 7.53 (m, 2H), 4.50 – 3.88 (m, 4H), 
3.76 (t, J = 4.8 Hz, 4H). 13C NMR (75 MHz, DMSO-d6) δ 165.4 (C), 155.2 (C), 154.5 
(CH), 154.2 (C), 133.5 (CH), 132.5 (C), 132.1 (CH), 131.9 (CH), 128.3 (CH), 125.1 
(C), 116.1 (C), 66.5 (CH2 × 2), 45.8 (CH2 × 2). HRMS (ESI) calcd. for C15H14O2N4Cl 
([M+H]+) 317.07998, found 317.07944. 
4.1.8.9. 2-(2-Chlorophenyl)-7-(4-methylpiperazin-1-yl)oxazolo[5,4-d]pyrimidine (40) 
The title compound was obtained as a yellow solid, mp 135-136 °C, purity 
(HPLC): 99.9%. 1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.14 – 8.07 (m, 1H), 
7.74 – 7.67 (m, 1H), 7.66 – 7.53 (m, 2H), 4.47 – 3.87 (m, 4H), 2.45 (t, J = 5.0 Hz, 4H), 
2.22 (s, 3H). 13C NMR (75 MHz, DMSO-d6) δ 165.4 (C), 155.0 (C), 154.5 (CH), 
154.1 (C), 133.4 (CH), 132.4 (C), 132.1 (CH), 131.8 (CH), 128.3 (CH), 125.1 (C), 
116.0 (C), 54.8 (CH2 × 2), 46.1 (CH3), 45.1 (CH2 × 2). HRMS (ESI) calcd. for 
C16H17ON5Cl ([M+H]
+) 330.11161, found 330.11082. 
4.1.8.10. 2-(2-Chlorophenyl)-7-(4-ethylpiperazin-1-yl)oxazolo[5,4-d]pyrimidine (41) 
The title compound was obtained as a yellow solid, mp 115-116 °C, purity 
(HPLC): 99.0%. 1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.14 – 8.08 (m, 1H), 
7.74 – 7.68 (m, 1H), 7.67 – 7.54 (m, 2H), 4.52 – 3.89 (m, 4H), 2.75 – 2.50 (m, 4H), 
2.47 – 2.32 (m, 2H), 1.05 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, DMSO-d6) δ 165.4 
(C), 155.1 (C), 154.5 (CH), 154.1 (C), 133.4 (CH), 132.5 (C), 132.1 (CH), 131.9 (CH), 
128.3 (CH), 125.1 (C), 116.0 (C), 52.5 (CH2), 51.9 (CH2 × 2), 44.8 (CH2 × 2), 12.2 
(CH3). HRMS (ESI) calcd. for C17H19ON5Cl ([M+H]
+) 344.12726, found 344.12641. 
4.1.8.11. 
1-(4-(2-(2-Chlorophenyl)oxazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)ethanone (42) 
The title compound was obtained as a yellow solid, mp 189-190 °C, purity 
(HPLC): 97.3%. 1H NMR (300 MHz, CDCl3) δ 1H NMR 8.43 (s, 1H), 8.17 – 8.07 (m, 
1H), 7.62 – 7.53 (m, 1H), 7.53 – 7.37 (m, 2H), 4.49 – 4.12 (m, 4H), 3.80 (t, J = 5.4 Hz, 
2H), 3.65 (t, J = 5.2 Hz, 2H), 2.19 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 169.3 (C=O), 
165.3 (C), 155.6 (C), 154.1 (C, CH), 133.5 (C), 132.2 (CH), 131.7 (CH), 131.3 (CH), 
127.1 (CH), 125.0 (C), 116.7 (C), 46.2 (CH2), 45.1 (CH2 × 2), 41.4 (CH2), 21.5 (CH3). 
HRMS (ESI) calcd. for C17H17O2N5Cl ([M+H]
+) 358.10653, found 358.10581. 
4.1.9. Synthesis of 2-(2-chlorophenyl)-7-(piperazin-1-yl)oxazolo[5,4-d]pyrimidine 
(31) 
The synthesis of 31 started from compound 30. The synthetic procedure is the 
same as in part 4.1.5. It was used for the next step directly. 
4.1.10. Synthesis of 2-(2-chlorophenyl)-7-(4-propylpiperazin-1-yl)oxazolo[5,4-d] 
pyrimidine (43) 
To a solution of compound 31 (0.15 mmol, 1 equiv) in 15 mL DMF were added 
Cs2CO3 (0.3 mmol, 2 equiv) and bromopropane (0.18 mmol, 1.2 equiv). The mixture 
was stirred and heated at 100 °C for 30 min. At the end of the reaction, after cooling, 
the solution was diluted with 50 mL saturated brine, and then extracted twice with 30 
mL ethyl acetate. The organic phase was washed twice with 50 mL distilled water and 
dried over MgSO4. The solvent was evaporated under reduced pressure to give target 
compound 43. The title compound is yellow solid, mp 136-137 °C, purity (HPLC): 
95.5%. 1H NMR (300 MHz, CDCl3) δ 8.38 (s, 1H), 8.14 – 8.07 (m, 1H), 7.59 – 7.53 
(m, 1H), 7.48 – 7.38 (m, 2H), 4.68 – 3.89 (m, 4H), 2.68 – 2.52 (m, 4H), 2.38 (t, J = 
7.7 Hz, 2H), 1.64 – 1.50 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 165.3 (C), 155.1 (C), 154.2 (C), 154.1 (CH), 133.4 (C), 131.9 (CH), 131.6 (CH), 
131.3 (CH), 127.0 (CH), 125.3 (C), 116.5 (C), 60.6 (CH2), 53.2 (CH2 × 2), 45.0 (CH2 
× 2), 19.9 (CH2), 11.9 (CH3). HRMS (ESI) calcd. for C18H21ON5Cl ([M+H]
+) 
358.14291, found 358.14179. 
4.1.11. Synthesis of N-(2-(2-chlorophenyl)-4-cyanooxazol-5-yl)acetamide (44) 
To solution of compound 13 (1 mmol, 1 equiv) in 30 mL NMP was added 
DIPEA (4 mmol, 4 equiv) and acetyl chloride (4 mmol, 4 equiv) dropwise, 
successively. The mixture was stirred and heated at 45 °C for 6 h. At the end of the 
reaction, after cooling, the solution was diluted with 200 mL saturated brine, and then 
extracted twice with 100 mL ethyl acetate. The organic phase was washed twice with 
150 mL distilled water and dried over MgSO4. The solvent was evaporated under 
reduced pressure. The crude product was used for the next step without purification. 
4.1.12. Synthesis of 2-(2-chlorophenyl)-5-methyloxazolo[5,4-d]pyrimidin-7-ol (45) 
A solution of crude 44 (0.5 mmol) in 30 mL 30% NaOH and 10 mL 35% H2O2 
(aqueous solution) was refluxed for 2 h. At the end of the reaction, the solution was 
acidified using 3 N HCl to pH 2 and a white flocculent precipitate appeared. The 
mixture was extracted twice with 30 mL ethyl acetate. The organic phase was washed 
twice with 50 mL distilled water and dried over MgSO4. The solvent was removed 
under reduced pressure. The residue was purified by silica gel column 
chromatography using CH2Cl2/ethyl acetate (6: 4 v/v) as eluent to give compound 45. 
4.1.13. Synthesis of 7-chloro-2-(2-chlorophenyl)-5-methyloxazolo[5,4-d]pyrimidine 
(46) 
The synthesis of 46 started from compound 45. The synthetic procedure is the 
same as in part 4.1.7. 
4.1.14. Synthesis of 2-(2-chlorophenyl)-5-methyl-7-(4-substituted piperazin-1-yl) 
oxazolo [5,4-d]pyrimidines (47-48) 
The synthesis of compounds 47-48 started from compound 46. The synthetic 
procedure is the same as in part 4.1.8. 
4.1.14.1. 
2-(2-Chlorophenyl)-5-methyl-7-(4-methylpiperazin-1-yl)oxazolo[5,4-d]pyrimidine 
(47) 
The title compound was obtained as a yellow solid, mp 151-152 °C, purity 
(HPLC): 99.5%. 1H NMR (300 MHz, CDCl3) δ 8.13 – 8.05 (m, 1H), 7.58 – 7.51 (m, 
1H), 7.46 – 7.37 (m, 2H), 4.68 – 4.07 (m, 4H), 2.81 – 2.62 (m, 4H), 2.59 (s, 3H), 2.44 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ 166.0 (C), 164.1 (C), 154.7 (C), 153.7 (C), 
133.3 (C), 131.7 (CH), 131.6 (CH), 131.2 (CH), 127.0 (CH), 125.4 (C), 114.3 (C), 
54.8 (CH2 × 2), 45.9 (CH3), 44.7 (CH2 × 2), 26.1 (CH3). HRMS (ESI) calcd. for 
C17H19ON5Cl ([M+H]
+) 344.12726, found 344.12607. 
4.1.14.2. 
2-(2-Chlorophenyl)-7-(4-ethylpiperazin-1-yl)-5-methyloxazolo[5,4-d]pyrimidine (48) 
The title compound was obtained as a yellow solid, mp 139-140 °C, purity 
(HPLC): 99.2%. 1H NMR (300 MHz, DMSO-d6) δ 8.06 (d, J = 7.7 Hz, 1H), 7.68 (d, J 
= 7.9, 1.6 Hz, 1H), 7.63 – 7.51 (m, 2H), 4.43 – 3.85 (m, 4H), 3.44 – 3.38 (m, 2H), 
3.30 – 3.22 (m, 2H), 2.47 (s, 3H), 2.37 (q, J = 7.2 Hz, 2H), 1.03 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 166.0 (C), 164.3 (C), 155.4 (C), 153.2 (C), 133.5 (C), 
132.0 (CH), 131.7 (CH), 131.2 (CH), 127.1 (CH), 125.1 (C), 114.6 (C), 52.6 (CH2 × 
2), 51.6 (CH2), 42.5 (CH2 × 2), 26.1 (CH3), 9.7 (CH3). HRMS (ESI) calcd. for 
C18H21ON5Cl ([M+H]
+) 358.14291, found 358.14184. 
4.2. Biological evaluation 
4.2.1. Competition binding assay 
Stock solutions of the compounds were prepared in DMSO and further diluted 
with the binding buffer to the desired concentration. Briefly, [3H]-CP-55,940 (0.5 nM), 
nonselective human CB1 and CB2 cannabinoid receptor, were added to 6 μg of 
membranes from CB1- or CB2-overexpressing CHO cells in binding buffer (50 mM 
Tris-HCl, 5 mM MgCl2, 2.5 mM EDTA, 0.5 mg/mL BSA, pH 7.4). After 90 min at 
30 °C, the incubation was stopped and the solutions were rapidly filtered over a 
UniFilter-96 GF/C glass fiber plate, presoaked in PEI (0.05%) on a Filtermate 
UniFilter 96-Harvester (PerkinElmer), and washed 10 times with ice-cold 50 mM 
Tris-HCl pH 7.4. The radioactivity on the filters was measured using a TopCount 
NXT microplate scintillation counter (PerkinElmer) using 30 μL of MicroScint 40 
(PerkinElmer). Assays were performed at least in three independent experiments in 
duplicate or triplicate. The nonspecific binding was determined in the presence of 5 
μM (R)-(+)-WIN 55,212-2 (Sigma). 
4.2.2. Cell culture and proliferation assay 
CHO-WT, CHO-CB2, and HT29 cells were grown at 37 °C in a humidified 
atmosphere containing 5% CO2, in HAM F12 medium or DMEM-GlutaMAX 
medium (for HT29 cells, Life Technologies) supplemented with 10% fetal bovine 
serum, penicillin (100 IU/mL), and streptomycin (100 μg/mL). In the cell 
proliferation assay, cells were plated in triplicate on 96-well plates (3 × 103 cells per 
well) and incubated for 24 h. Cells were then incubated in culture medium that 
contained 10 μM test compounds. After 72 h, cell growth was estimated by the 
colorimetric MTS test. 
4.2.3. Cell-based HTRF cAMP assay 
Cellular cAMP levels were measured using reagents supplied by Cisbio 
International (HTRF dynamic 2 cAMP kit). Briefly, CHO-CB2 cells were harvested 
and were collected by centrifugation for 5 min at 1200 rpm. The cells were then 
resuspended in an appropriate final volume of culture medium and incubated with the 
phosphodiesterase inhibitor IBMX (0.5 mM). Cells were incubated for 15 min with 
the compounds at room temperature in a 384-well plate (2000 cells per well) before 
the addition of forskolin (3 µM) for 30 min at room temperature. The dye 
d2-conjugated cAMP and Europium cryptate-conjugated anti-cAMP antibodies were 
added to the assay plate, according to manufacturer’s instructions. After 1 hour 
incubation at room temperature, the plate was read on a Spectramax microplate reader 
(Molecular Devices) with excitation wavelength at 340 nm and emission wavelengths 
at 665 nm and 620 nm. Assays were performed at least in three independent 
experiments in duplicate or triplicate. 
4.2.4. Metabolic stability in mice liver microsomes 
The 1 µM compounds tested and referenced were incubated in duplicate (0.5 mL 
reaction volume) with male mice (CD-1) liver microsomes (20 mg/mL, BD 
Gentest™) at 37 °C in 50 mM phosphate buffer (5 mM MgCl2, 1 mM NADP, 0.4 
U/mL glucose-6-phosphate dehydrogenase, and 5 mM glucose-6-phosphate, pH 7.4). 
For the estimation of CLint: sampling of a 50 μL aliquot at 0, 5, 10, 20, 30 and 40 min, 
and the reaction was stopped by 4 volumes of acetonitrile containing the internal 
standard (200 nM compound 40 or 200 nM compound 42). After centrifugation at 
10000 g, 10 min, 4 °C, the supernatants were kept at 4 °C to be analyzed immediately 
(or placed at -80 °C if the analysis was postponed). Controls (t0 and tfinal) in triplicate: 
incubation with microsomes denatured by acetonitrile containing the internal 
standard. Propranolol was used as a positive control. Analysis was determined by 
UPLC-MS/MS (Waters* Acquity I-Class / Xevo TQD) using a column (Waters* 
Acquity BEH C18, 50 x 2.1 mm, 1.7 μm; mobile phase: A: 10 mM ammonium 
ethanoate, B: CH3CN 0.1% HCOOH). Retention time was obtained with flow rates of 
600 μL/min. The acquisition time is 4 min. 
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